Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
AssigneeShire ViroPharma Incorporated
InventorsWalter Tatarowicz, Colin Broom
Life of this patent
Estimating the term…
Abstract
Compositions and methods for inhibiting Clostridium associated diseases are disclosed.
Claims41
A method of inhibiting disease caused by Clostridium in a subject, said method comprising:
- a) providing a first subject that has been administered a non-toxigenic strain of said Clostridium, and that retains an amount of said non-toxigenic Clostridium effective to cause shedding of said non-toxigenic Clostridium by said first subject;
- b) administering at least one antibiotic to a second subject;
- and
- c) exposing said second subject to said first subject, wherein the exposure of said second subject to said first subject results in the colonization of the gastrointestinal tract of said second subject by said non-toxigenic Clostridium.
A method of inhibiting disease caused by Clostridium in a subject, said method comprising:
- a) administering at least one antibiotic to said subject;
- and
- b) contacting the environment of said subject with an effective amount of a non-toxigenic strain of said Clostridium, wherein said subject is maintained in said environment for a time sufficient to allow the colonization of the gastrointestinal tract of said subject by said non-toxigenic Clostridium.
A composition comprising a pharmaceutically unacceptable carrier and at least one non-toxigenic strain of Clostridium.
A method of producing a non-toxigenic strain of C. difficile comprising administering to an animal host a sufficient quantity of said non-toxigenic strain of C. difficile spores to induce colonization of the gastrointestinal tract of said host by said spores, thereby causing shedding of said spores by said host.
A method of protecting a patient undergoing medical treatment at a treatment site from acquiring a disease caused by a Clostridial infection while present at said site, the method comprising dispersing a non-toxic strain of C. difficile at said site in an amount sufficient to be transferred to said patient, thereby effecting colonization of the gastrointestinal tract of said patient by said non-toxigenic strain of C. difficile.
A method of reducing the risk that a medical treatment site will induce a disease caused by a Clostridial infection in a patient upon undergoing treatment at said site, the method comprising dispersing a non-toxic strain of C. difficile at said site in an amount that is sufficient to be transferred to a patient exposed to said site, to thereby effect colonization of the gastrointestinal tract of said patient by said non-toxigenic strain of C. difficile.
Dependencies are inferred from the claim text.